841-67-8
基本信息
(-)-沙利度胺
(S)-(-)-THALIDOMIDE
6-dioxo-3-piperidyl)-n-(l-(-)-phthalimid
N-[(S)-2,6-Dioxopiperidine-3-yl]phthalimide
(-)-THALIDOMIDE >98% INHIBITOR OF ANGIOG EN
(-)-N-[(S)-2,6-Dioxo-3-piperidinyl]phthalimide
6-dioxo-3-piperidinyl)-3(2h)-dion(s)-1h-isoindole-2-(2
(3S)-3-(1,3-Dioxo-2H-isoindole-2-yl)piperidine-2,6-dione
2-[(3S)-2,6-Dioxo-3-piperidyl]-1H-isoindole-1,3(2H)-dione
S(-)-2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3(2H)-DIONE
物理化学性质
| 熔点 | 269-271°C |
| 沸点 | 401.48°C (rough estimate) |
| 密度 | 1.2944 (rough estimate) |
| 折射率 | 1.5300 (estimate) |
| 储存条件 | -20°C冷冻 |
| 溶解度 | DMSO: soluble |
| 酸度系数(pKa) | 10.70±0.40(Predicted) |
| 形态 | solid |
| 颜色 | white |
| 旋光度 (Optical Rotation) | [α]23/D 62.6°, c = 2 in DMF(lit.) |
| InChI | InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1 |
| InChIKey | UEJJHQNACJXSKW-VIFPVBQESA-N |
| SMILES | C1(=O)C2=C(C=CC=C2)C(=O)N1[C@H]1CCC(=O)NC1=O |
安全数据
| 危险性符号(GHS) |   GHS07,GHS08 |
| 警示词 | 危险 |
| 危险性描述 | H302-H360 |
| 防范说明 | P201-P301+P312+P330-P308+P313 |
| 危险品标志 | T |
| 危险类别码 | 61-22 |
| 安全说明 | 53-36/37/39-45 |
| 危险品运输编号 | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS号 | TI4925050 |
| 存储类别 | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
| 危险性类别 | Acute Tox. 4 Oral Repr. 1B |
(-)-沙利度胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-14658A | (-)-沙利度胺 (S)-Thalidomide | 841-67-8 | 5 mg | 700元 |
| 2026/09/15 | HY-14658A | (-)-沙利度胺 (S)-Thalidomide | 841-67-8 | 10 mM * 1 mL in DMSO | 770元 |
| 2026/09/15 | HY-14658A | (-)-沙利度胺 (S)-Thalidomide | 841-67-8 | 10 mg | 1100元 |
常见问题列表
Apoptosis
(S)-Thalidomide treatment results in a reduction in cell viability in U266 cells with an IC
50
of 362 μM.
(S)-Thalidomide treatment increased apoptosis in a dose-dependent manner in U266 cells.
There are changes in the expression profile of genes involved in angiogenesis and apoptosis, but the changes are most dramatic in the apoptotic genes. In particular, the expression of I-κB kinase is decreased by two-fold, which is associated with a four-fold decrease in NF-κB expression. (S)-Thalidomide increases the Bax:Bcl-2 ratio, also increases I-kB protein levels, and decreases NF-kB activity. A dramatic decrease in Bcl-2 expression with (S)-Thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents.
Cell Viability Assay
| Cell Line: | U266 MM cells |
| Concentration: | 0 µM, 10 µM, 100 µM, 150 µM, 200 µM, 1000 µM |
| Incubation Time: | 3 days |
| Result: | A reduction in cell viability was observed in U266 cells. |
Apoptosis Analysis
| Cell Line: | U266 MM cells |
| Concentration: | 100 µM, 150 µM, 200 µM, 1000 µM |
| Incubation Time: | 3 days |
| Result: | Increased apoptosis in U266 cells. |
Thalidomide does cause limb reduction defects in chick embryos as long as the embryos are directly exposed to the drug. The most useful techniques are implanting Thalidomide-soaked beads into the embryo immediately adjacent to the limb territory or soaking presumptive chick limb territories in Thalidomide and then grafting the explants to a host embryo celom. Thalidomide affects the chick limb grafted to a host embryo in a dose response fashion. Furthermore, (S)-Thalidomide is more teratogenic than (R)-Thalidomide.